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Background: In the management of malignant pleural mesothelioma, radiotherapy has been
used  for the purpose of prophylaxis to reduce the incidence of recurrence at surgical inser-
tion sites or palliate the symptoms.
Aim: The purpose of the study was to evaluate the techniques and effectiveness of radio-
therapy in malignant pleural mesothelioma.
Materials and methods: Forty-four (18 female, 26 male) patients diagnosed with malignant
pleural mesothelioma were retrospectively evaluated. All patients had surgery or thoraco-
scopic biopsy for diagnosis, staging or treatment and all received palliative or prophylactic
radiotherapy. Fifty-seven percent of the patients received chemotherapy.
Results: Prophylactic radiation was applied to 27 patients with 4–15 MeV electron energies.
The median radiotherapy dose was 30 Gy with 3 Gy daily fraction dose. During treatment,
12  patients had grade 1 erythema according to the RTOG scale. In 3 (12%) patients, a local
failure at treatment ﬁeld was observed. Palliative radiotherapy was applied to 17 patients for
pain palliation. The median radiation dose was 40 Gy with 2 Gy daily fraction dose by using
6–18  MV photon and/or 4–12 MeV electron energies. Two patients had grade 1 erythema and
one  patient had grade 2 odynophagy according to the RTOG scale. For 10 (59%) patients,
palliation of chest pain was delivered. No late toxicity was observed for all cases.
Conclusion: Our experience showed that prophylactic and palliative radiotherapy are effec-
tive and safe therapy modalities in malignant pleural mesothelioma in preventing seedingmetastasis at intervention sites or relieving pain. Prospective randomized studies are still
needed to determine the beneﬁts of radiotherapy application and to indicate optimum dose
schemes.
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.  Background
alignant pleural mesothelioma (MPM)  is a relatively rare tho-
acic tumor which is originates from the lining cells of the
leura.1 The incidence of MPM  is expected to increase over
he next decade in most industrial countries and in the coun-
ries with poor regulations of asbestos mining, production
nd household use.2,3 The domestic usage of soil mixed with
sbestos causes a major health problem in Turkey, especially
n Eastern and South Eastern Anatolia. A mineral other than
sbestos named ﬁbrous zeolyte (erionite) is accepted to be one
f the most powerful carcinogens and was found in some rocks
sed in the construction of houses and in the walls of caves
sed as storerooms in the villages of the Cappadocia region
n Turkey.4 Asbestos and erionite are known factors in the eti-
logy of MPM.  Although it varies between series, there is a
ontact with asbestos in 70–80% of cases.5–7
MPM  is considered as an aggressive disease with dismal
rognosis. Median survival varies between 9 and 17 months.8,9
ocal disease progression is the main cause of death.10,11 The
ajor problem is poor control of local disease and the dissem-
nation of MPM  through the drain sites and tracks of chest wall
nstrumentation.10 There is no deﬁnite standard of care, only
 minority of patients are eligible for curative therapy. Single
odality treatment [surgery, radiotherapy (RT) or chemother-
py] have generally failed to signiﬁcantly improve survival.12
ultimodality aggressive therapy seems to improve local con-
rol and survival, but the beneﬁts of this approach have
een questioned because of treatment related morbidity and
ortality.12,13 Although radical surgery has been advocated,
ost cases cannot be operated due to surgical or medical
noperability.14 Many  single and combined chemotherapeutic
gents have been tried and reviews describe modest success
ith several agents.15,16 As RT has never been compared to
hemotherapy or surgery or best supportive care in prospec-
ive randomized trials, there exist no data to support one or
he other therapies as a better option.17
MPM  is tradionally thoght to be radioresistant, however,
umor cells derived from MPM  were found to be more  sensitive
o radiation than non-small cell lung carcinoma.18 In the man-
gement of MPM,  RT is used in three ways: as prophylaxis to
educe the incidence of recurrence at sites of diagnosis or ther-
peutic instrument insertion, or in a multimodal treatment
o improve locoregional control after resection of early-stage
isease and to palliate symptoms for patients with advanced
isease.7 Mesothelial tumor cells seeding through the instru-
ent tracts after pleural intervention occurs in around 20%,
ut may be as high as 50%.19–21 In the presence of seeding
etastasis, the lesion can be extremely painful and difﬁcult to
alliate with RT,21 and surgery is the only effective procedure
f applicable.10 For this reason, prophylactic RT to drain sites
r incision scars is the main preventing option.7,21 However,
o clear consensus on the beneﬁt of prophylactic RT can be
eached, because the trials have conﬂicting results.7,12 More-
ver, RT has been applied to relieve symptoms associated with
PM.  Althogh previous studies had conﬁmed that RT can pal-
iate chest pain in nearly 60% of patients,22–24 no optimal RT
ose and fractionation scheme has been speciﬁed from these
tudies.iotherapy 1 8 ( 2 0 1 3 ) 82–86 83
2.  Aim
Rarity of this disease and few available retrospective and
prospective data led us to review our experience. The purpose
of this study was to evaluate the tecniques and effectiveness
of RT when given on a prophylactic and palliative basis either
alone or combined with chemotherapy in MPM patients.
3.  Materials  and  methods
We  retrospectively evaluated the ﬁles of cases with MPM,
treated at Gazi University Faculty of Medicine, Department
of Radiation Oncology between 1996 and 2010. The informed
consent form was obtained from all patients. Forty-four
patients (18 female, 26 male) with a median age of 55 (range
36–84) years at diagnosis were assessed. Dyspnea (87%), chest
pain (75%) and cough (65%) were the most common present-
ing symptoms. All patients’ Karnofsky Performance Statuses
were ≥70. These patients underwent detailed investigations
before therapy. Routine blood tests, chest X-ray, chest and
abdomen computed tomography, pulmonary function testing,
and, more  recently, positron emission tomography were per-
formed. The MPM  diagnoses were histopathologically proven
for all cases. Epitheloid subtype was reported in 38 (86.4%)
patients while biphasic subtype in 6 (13.6%) patients. Video-
assisted thorascopic surgery (VATS) and pleural biopsy were
applied to 9 (20.5%) patients, 9 (20.5%) patients had pleural
decortications, 2 (4.5%) patients had thoracotomy and wedge
resection, 2 (4.5%) patients had thoracotomy and pleurode-
sis, 5 (11.4%) patients had biopsy and pleurodesis and 17
(38.6%) patients had only biopsy. Twenty-ﬁve (57%) patients
received chemotherapy and different drug regimens were
used. Most patients received gemcitabin and cisplatin or
cisplatin and pemetrexed and remaining patients received
different protocols including ifosfamide, epirubicin and adri-
amicin. Chemotherapy was usually applied in 4–6 cycles. All
patients received RT. Six weeks after completion of RT and
within 3 months’ interval thereafter, patients were followed-
up with physical examination, routine blood chemistry, chest
X-ray and/or computed tomography. If any suspicious lesions
were observed, biopsies were taken for histopathological con-
ﬁrmation. For the evaluation of pain response, patients were
revised at 1 month after completion of RT. Evaluation of pain
relief (patient reported) or other symptomatic response was
based on patient records. Pain was evaluated by using a visual
analog scale.
The statistical analysis was performed by using the Statis-
tical Package for Social Sciences software package, version 13
(SPSS Inc., Chicago, IL, USA). Patients and treatment character-
istics were described using median, mean, standard deviation
and range (minimum–maximum) for continuous variables.
The follow-up time was estimated from initial date of RT to
date of death or last follow-up. The survival time was esti-
mated from date of the histopathologic diagnosis to date of
death or last follow-up. The survival analysis was performed
by using the Kaplan–Meier method.
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Table 1 – Prophylactic radiotherapy features and
treatment responses.
aRT planning (n = 27)
b2DCRT: 13 (48.2%)
c3DCRT: 14 (51.8%)
aRT dose-fractionation schedules
Total aRT dose: median 36 (range: 21–42) Gy
Daily aRT dose: median 3 Gy (range: 2–7) Gy
Fraction numbers: median 12 (range: 3–21)
Treatment response
Local and distant failure Patients (n, %)
aRT ﬁeld 3 (12)
Ipsilateral hemithorax 7 (28)
Ipsilateral hemithhorax + mediastinum 4 (16)
Contralateral 2 (8)
Distant metastasis 6 (24)
Survival
Mean survival time: 12.6 ± 1.3 (10–15) months
1 year survival rate: 61%
2 year survival rate: 4%
a RT, radiotherapy.
b 2DCRT, two dimensional conventional radiotherapy.
c 3DCRT, three dimensional conformal radiotherapy.
4. Results
Twenty-seven (61.4%) patients received RT for prophylaxis,
17 (38.6%) patients received RT for palliation. Twenty-three
(52.3%) patients received conventional RT and 21 (47.7%)
patients received three dimensional conformal RT (3DCRT).
Conventional two dimensional RT (2DCRT) was applied to
13 (48.2%) and three dimensional conformal RT (3DCRT) was
applied to 14 (51.8%) 27 patients in the prophylactic intent
(Table 1). Palliative 2DCRT was performed for 10 (58.8%)
patients while 7 (41.2%) patients received 3DCRT (Table 2).
For conformal RT, computed tomography planning scans
were used. On each tomography slice clinical target volume
Table 2 – Palliative radiotherapy features and treatment
responses.
aRT planning (n = 17)
b2DCRT: 10 (58.8%)
c3DCRT: 7 (41.2%)
aRT dose-fractionation schedules
Total aRT dose: median 40 (range: 20–60) Gy
Daily aRT dose: median 2 Gy (range: 2–4) Gy
Fraction numbers: median 12 (range: 5–30)
Treatment response
Local and distant failure Patients (n, %)
Progression in aRT ﬁeld 4 (25)
Outside aRT ﬁeld 6 (37.5)
Distant metastasis 3 (19)
Outside aRT ﬁeld + distant metastasis 3 (19)
Survival
Mean survival time: 11.6 ± 0.9 (10–13) months
1 year survival rate: 53%
2 year survival rate: none
a RT, radiotherapy.
b 2DCRT, two dimensional conventional radiotherapy.
c 3DCRT, three dimensional conformal radiotherapy.diotherapy 1 8 ( 2 0 1 3 ) 82–86
(CTV), planning target volume (PTV) and organ at risk (OAR)
were contoured. For prophylactic 3DCRT, all procedure scar
sites (ﬁne needle biopsy, drainage, thoracoscopy, thoracotomy,
pleurectomy); for palliative 3DCRT, all sites of symptomatic
and bulky disease were included in CTV.
Prophylactic RT was applied after healing of the surgical
scars, 8–69 (mean 35) days after procedure. For prophylactic
radiation, 1–1.5 cm margin was added to incision or dren scars.
The appropriate electron energies such as 4–15 MeV were used
for 35 drain sites (minimum one maximum three sites for
each patient). The median RT dose was 30 Gy with 3 Gy daily
doses. In some cases, bolus material was used. The RT was
well tolerated. During RT, 12 (44.4%) patients developed grade
1 erythema [Radiation Therapy Oncology Group (RTOG) scale].
RTOG ≥grade 2 acute skin toxicity was not observed. No late
complications (such as skin ﬁbrosis, necrosis or lung toxic-
ity) were observed. The response of prophylactic radiotherapy
was evaluated for 25 patients, because two patients were lost
to follow-up. In 3 (12%) patients, local failure at the radiation
treatment ﬁelds was observed. Local and distant recurrences
were seen in 17 of 25 patients. The most metastatic site was
the bone. Twenty-two of 25 patients died after a mean follow-
up time of 10.5 (1.3–28) months. The mean survival time was
12.6 months. Prophylactic RT dose-fractionation schedules
with treatment response are summarized in Table 1.
Palliative RT was applied to 17 patients with local-advanced
stage MPM for pain palliation. The median RT dose was 40 Gy
with 2 Gy daily fractions by using 6–18 MV photon and/or
4–12 MeV electron energies. For one patient, Co60 device was
used. For one ﬁeld the total dose remained at 26 Gy due to
patient’s own request for leaving the therapy. Therefore, he
was excluded from the analysis of treatment response. The
median duration of pain relief was found to be 3 (2–6) months.
RT was well tolerated. During RT, 2 (11.8%) patients had grade
1 erythema and 1 patient (5%) developed grade 2 odynophagy
according to RTOG scale. No radiation induced pneumonia
and no late complications (such as skin or lung ﬁbrosis) were
observed. For 10 (59%) patients, chest pain relief was reported.
In 10 patients local failure, in 3 patients distant metastasis
and in 3 patients local failure and distant metastasis were
observed. All patients died after a mean follow-up time of 6.9
(0.6–16.5) months. The mean survival time was 11.6 months.
The palliative RT dose fractionation schedules with treatment
results were summarized.
5.  Discussion
Retrospective studies have reported that prophylactic RT can
prevent MPM  metastasis in surgical intervention sites.25,26
However, three small prospective trials have had conﬂicting
results. The ﬁrst randomized phase III study from France19
compared the 20 patients who had received prophylactic RT to
surgical sites to 20 patients who had not received RT. Patients
were treated with 21 Gy in 3 fractions by using 12–15 MeV elec-
trons. No patients in the irradiated group had recurrence along
intervention sites, whereas 40% of patients had metastatic
nodules in the non-irradiated group. On the other hand, the
randomized clinical trial from England27 showed no beneﬁt of
prophylactic RT. In this study, 31 MPM patients, who  had had
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leural invasive procedure, received 21 Gy in 3 fractions using
50 kV or 9–12 MeV  electrons, another 30 patients received
est supportive care. No statistically signiﬁcant difference was
ound in the risk of tract metastasis between the arms. In
he third trial conducted in Australia,28 28 patients received
0 Gy in a single fraction using 9 MeV  electrons within 15 days
f invasive procedure. Thirty patients did not receive radia-
ion. The difference in tract metastasis between the groups
as not signiﬁcant. However, the authors indicated that 9 MeV
ay have been inadequately penetrating. It is difﬁcult to
educe a conclusion from these results. Since all three trials
ncluded small numbers of patients and the radiation tech-
iques used different dose-fractionation Schemes.7 Based on
xisting data, no clear consensus can be reached as to the ben-
ﬁt of prophylactic radiation. However, despite the absence of
arge randomized controlled trials, the reported series showed
hat most of the clinicians preferred to apply prophylactic RT.
ecently, a survey practice in the Netherlands and Belgium
howed that 32 of 38 centers that responded to questionnaire
ecommended prophylactic radiation to intervention sites26
nd a study from the United Kingdom showed that 75% of 23
ncology centers offered to use prophylactic RT.29
In our department, the general approach is applying
rophylactic radiation to intervention sites. Although there
as no consensus on dose fractionation schedule, hypo-
ractionated schemes were mostly preferred and applied
ithin a mean of 35 days after procedure. In the literature,
he optimum dose and timing of RT has not been clear, how-
ver, based on retrospective studies hypo-fractionated RT has
requently been a preferred regimen.19,26,30 The National Com-
rehensive Cancer Network (NCCN) recommends doses of
1 Gy in 3 fractions for prophylaxis. Although in recent years
1 Gy has been preferred in our department, the most used
chedule being 36 Gy in 12 fractions. The reason to use 36 Gy
as that according to the isoeffective dose formula, when the
/  ˇ ratio was accepted as 1.7 due to subcutan tissue for late
eactions,31 the effectiveness of 36 in 12 fractions was equal
o 46 Gy in 23 fractions, radiobiologically, which was accepted
ufﬁcient dose for prophylaxis.
In several reports, RT was applied within 2–3 weeks after
urgery.25,27,32 It is difﬁcult to draw deﬁnitive conclusions
s to the timing of prophylactic RT. Actually, best timing
or delivering radiation after surgical intervention should be
etermined by a multidisciplinary team. In our hospital, start-
ng prophylactic RT within 3–6 weeks after surgery has been
ecommended. Our results indicated that prophylactic RT was
n effective and safe treatment modality for patients with
PM.  One difference of this trial from several previous stud-
es is that 3DCRT was applied to 52% of the patients. This can
e one of the reasons for observing minimal side effects with
igh local control ratios due to obtaining more  homogenous
ose distribution while protecting more  surrounding normal
issues compared to conventional RT technique.
Chest wall pain is one of the frequent symptoms of MPM.
he studies that evaluated the effectiveness of palliative RT
ere usually retrospective and an optimum dose and frac-ionation scheme was not clear. In an early retrospective trial,
9 courses were given to 19 patients with doses of 40–50 Gy
nd effective palliation was associated with ≥40 Gy RT.32 In
nother study, 21 patients undergoing a total of 31 courses ofiotherapy 1 8 ( 2 0 1 3 ) 82–86 85
palliative RT were evaluated. Short courses of RT (20 Gy in 5
fractions) seemed to be as effective as longer courses (30 Gy in
10 fractions) of RT for relieving the symptoms.33 Bissett et al.22,
prospectively assessed the pain response of a large ﬁeld RT
given to the hemithorax to a dose of 30 Gy in 10 fractions. In
that study, the effectiveness on pain palliation was evaluated
by using a visual analog scale and the consumption of anal-
gesics before and after RT. Pain control was obtained in 13 of
19 (68%) patients at 1 month after RT. However, this response
was short-lived; In 9 of 12 patients, chest pain worsened by
3 months. Similar results were found in another retrospec-
tive analysis. Higher local response rates for patients treated
with 36 Gy applied using 4 Gy per fraction were compared to
those receiving 30 Gy with less than 4 Gy per fraction (50% vs.
39%). The evaluation of response was based on patients’ report
and the use of analgesics. The duration of pain relief was
again short and it was recurred at a median of 69 days after
RT.24 The criticism of these reports is the following; patient
numbers were small, RT techniques used in most cases were
obsolete, and measures of symptom control were not stan-
dardized. In our study, palliative RT was applied to 17 patients
for pain palliation. Total doses were heterogeneous such as
in other retrospective studies and varied from 20 Gy to 60 Gy.
This variation could result from the necessity of applying RT to
large ﬁelds such as one hemithorax for controlling the symp-
toms. Therefore, the clinicians were compelled to modify the
RT dose and fractions according to the existence of poor per-
formance status and co-morbidities of the patients and the
extensive irregularly in the shape of tumors. Forty-percent of
patients received 3DCRT and at most cases the total doses
were reduced to prevent early and late toxicities at many  crit-
ical structures such as the heart, lung and spinal cord as a
consequence of large RT volume and large fraction size. Usu-
ally, a preferred RT schedule was 40 Gy delivered by 4 Gy per
fraction. As it was emphasized before that the effective pal-
liation can be obtained with this regimen. At 1 month after
completion of RT, pain control was achieved in 59% of patients.
However, the duration of pain relief was not mentioned and
assessment of RT efﬁcacy on pain control was based on our
patients’ perception, which is subjective. In a recent study,
it was shown that a signiﬁcant volume of disease was omit-
ted from the target volume in 3BCRT; since it was difﬁcult
to encompass all the tumor due to dose constraints imposed
by adjacent organs. The authors stated that deﬁning parts of
the tumor responsible for symptoms and deﬁning the dura-
tion of pain control is difﬁcult, by its nature which is highly
subjective.29
6. Conclusions
Our experience showed that prophylactic and palliative RT are
effective and safe therapy modalities for MPM  patients. Major
drawbacks of our study are its retrospective nature, small
number of patients and heterogeneity in dose-fractionation
RT schemes. The necessity of prophylactic irradiation is still
controversial, however, as seeding metastasis are painful,
applying prophylactic radiation can be preferred to improve
patients’ quality of life. Palliative RT can certainly be of some
beneﬁt in palliating chest pain, but its duration is often short.
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Although at present, no validated assessment of RT effec-
tiveness for palliation is available, palliation of symptoms
and pain relief remain important in patient care. Prospective
randomized studies are needed to determine the beneﬁts of
prophylactic or palliative RT application and to indicate the
optimum dose schedules.
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